Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Abraham

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
NPJ Breast Cancer|January 8, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)Laura M Spring, Lauren Scarpetti, Arielle J Medford, et al.
JCO Oncology Practice|November 3, 2023
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community CollaborationLaura M Spring, Lindsey Mortensen, Elizabeth Abraham, et al.
Blood|January 21, 2022
Structural racism is a mediator of disparities in acute myeloid leukemia outcomesIvy Elizabeth Abraham, Garth H Rauscher, Anand Ashwin Patel, et al.
Blood|October 16, 2025
Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical TrialsAndrew Hantel, Yating Wang, Angel Cronin, et al.
Journal of the American Society of Nephrology : JASN|October 29, 2014
HLA-DQA1 and PLCG2 Are Candidate Risk Loci for Childhood-Onset Steroid-Sensitive Nephrotic SyndromeRasheed A Gbadegesin, Adebowale Adeyemo, Nicholas J A Webb, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
NPJ Breast Cancer|January 8, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)Laura M Spring, Lauren Scarpetti, Arielle J Medford, et al.
JCO Oncology Practice|November 3, 2023
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community CollaborationLaura M Spring, Lindsey Mortensen, Elizabeth Abraham, et al.
Blood|January 21, 2022
Structural racism is a mediator of disparities in acute myeloid leukemia outcomesIvy Elizabeth Abraham, Garth H Rauscher, Anand Ashwin Patel, et al.
Blood|October 16, 2025
Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical TrialsAndrew Hantel, Yating Wang, Angel Cronin, et al.
Journal of the American Society of Nephrology : JASN|October 29, 2014
HLA-DQA1 and PLCG2 Are Candidate Risk Loci for Childhood-Onset Steroid-Sensitive Nephrotic SyndromeRasheed A Gbadegesin, Adebowale Adeyemo, Nicholas J A Webb, et al.
Pageof 5